Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619863 | 0.82 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL10145405 | 0.75 | CHRNA3 (0.54) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL10121975 | 0.73 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL1367407 | 0.69 | PARP15 (0.40) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL607998 | 0.65 | NPC1 (0.35) | CHRNB2CHRNA4CYP2D6CYP3A4 | |
| SCHEMBL610705 | 0.64 | CHRNB2 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL7862956 | 0.64 | CHRNB2 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL695403 | 0.64 | CHRNB2 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL611439 | 0.64 | CHRNB2 (0.33) | CHRNB2CHRNA4 | |
| SCHEMBL10121582 | 0.63 | HPGD (0.38) | CHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2010122151-A1 | 3 -AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | CHRNB2 120/4885CHRNA4 69/4885CHRNA3 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.